Tag Archives: healthcare costs

Medicare Payment Data Raises Questions About Drug Costs

Even though the just-released Medicare data on payments to individual doctors doesn’t provide specifics on prescription drug outlays, it opens the door to sharp scrutiny of Medicare reimbursement for medicines delivered in physician offices. The Centers for Medicare and Medicaid Services (CMS) has released data on payments to some 880,000 health care providers who collectively […]
Posted in healthcare, Legal, pricing, Regulatory | Also tagged , , | Leave a comment

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Posted in healthcare, leadership, Market Access, pricing, R&D, Regulatory, Safety, Strategy | Also tagged , , , , | Leave a comment

PCORI Initiatives May Support More Drug Comparisons

The Patient-Centered Outcomes Research Institute (PCORI) is launching new programs that are expected to encourage more analysis of the effectiveness of specific drugs and medical products, while also building infrastructure that could support clinical research on biopharmaceutical products. Since it was established by the 2010 health reform legislation, PCORI has  devoted much of its resources […]
Posted in R&D, Regulatory | Also tagged , , , , , , , , | Leave a comment

Into the Extrapolation Machine: How We Joined the Elite 58%

By Les Funtleyder. The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof. With respect to investing, uncertainly caused by media/pundit noise often depresses valuations […]
Posted in Guest Blog, healthcare, Op-Ed | Also tagged , , , , , , , , , | Leave a comment

Talkback from Tufts: Defending R&D Costs

by Joe DiMasi, director of economic analysis, Tufts Center for the Study of Drug Development William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.  Both the posting and the working paper by F.M. Scherer on which the posting was […]
Posted in Guest Blog, pricing, R&D | Also tagged , | 2 Comments
  • Categories

  • Meta